Health NewsLocal NewsNorthern Rivers Local News

PBS Additions for Cancer and Epilepsy Bring New Hope to Patients

PBS Additions for Cancer and Epilepsy Bring New Hope to Patients

 

Tens of thousands of Australians are set to benefit from the Federal Government’s latest additions to the Pharmaceutical Benefits Scheme (PBS), including life-saving medications for cancer and epilepsy. The newly listed treatments are expected to save patients hundreds of thousands of dollars annually.

Among the new additions is Zyamis (midazolam), now available in pre-filled syringes for the emergency treatment of potentially life-threatening seizures in patients with epilepsy. This medication is used to treat generalised convulsive status epilepticus, a severe form of epilepsy where seizures last more than five minutes, risking long-term brain damage if not treated swiftly. Previously, patients would have paid $270 per prescription without the PBS subsidy. The listing of Zyamis will benefit over 10,000 Australians living with epilepsy.

Another significant inclusion is Tecentriq SC (atezolizumab), now available in a new subcutaneous form that allows it to be administered via injection. This will make treatment more accessible for more than 2,700 Australians with lung and liver cancer, potentially saving them hours of hospital time. Prior to the PBS listing, this life-saving medication cost $120,000 per year.

For children over two years old with symptomatic, inoperable benign nerve tumours associated with neurofibromatosis type 1, a rare genetic disorder, Koselugo (selumetinib) has been listed for the first time. This addition is expected to benefit around 170 children, whose families would otherwise face treatment costs of approximately $146,000 per year.

Onpattro (patisiran), used to treat hereditary transthyretin-mediated (ATTR) amyloidosis, has also been listed on the PBS for the first time. This rare condition’s treatment will now be affordable for around 55 patients each year, who would otherwise pay an astounding $647,500 annually.

Additionally, the PBS listing for Vitrakvi (larotrectinib) has been expanded to include the treatment of adults with locally advanced or metastatic non-small cell lung cancer or soft tissue sarcoma solid tumours that have a specific gene fusion known as neurotrophic tropomyosin receptor kinase.

These new PBS listings mark a significant step forward in providing affordable, life-saving treatments to Australians suffering from severe health conditions, offering renewed hope and financial relief to thousands of patients and their families.

 

For more health news, click here.

Kyogle News, Richmond Valley News, Clarence Valley News, Lismore News, Ballina News, Byron News, Tweed News, Gold Coast News, Coffs Harbour News

Related posts

Cheat’s Mille-Feuille – Fancy French Dessert for People Who Can’t Be Bothered

News Desk

Rough night on the water

News Desk

NBN Hosting Free Community Sessions in Kyogle

JeffG